drugset / Trial / NCT05190445
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinrebafusp alfa | Other / unclassified | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Ramucirumab | Monoclonal antibody | — | — |
| Background | Tucatinib | Small molecule | — | — |